These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 24222095)

  • 21. Plasma adiponectin is a more specific marker of fatty liver than a marker of metabolic syndrome in Japanese men.
    Yatsuzuka S; Shimomura Y; Akuzawa M; Ando Y; Kobayashi I; Nakano T; Tokita Y; Nagamine T; Ono H; Tanaka A; Schaefer E; Nakajima K
    Ann Clin Biochem; 2014 Jan; 51(Pt 1):68-79. PubMed ID: 23897104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.
    Corey KE; Vuppalanchi R; Vos M; Kohli R; Molleston JP; Wilson L; Unalp-Arida A; Cummings OW; Lavine JE; Chalasani N;
    J Pediatr Gastroenterol Nutr; 2015 Mar; 60(3):360-7. PubMed ID: 25714579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
    Sahebkar A; Chew GT; Watts GF
    Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study.
    Borén J; Watts GF; Adiels M; Söderlund S; Chan DC; Hakkarainen A; Lundbom N; Matikainen N; Kahri J; Vergès B; Barrett PH; Taskinen MR
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2218-24. PubMed ID: 26315407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study.
    Dusejovska M; Stankova B; Vecka M; Rychlíkova J; Mokrejsova M; Rychlík I; Zak A
    Curr Vasc Pharmacol; 2018; 16(3):298-305. PubMed ID: 28554308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormalities of lipoprotein concentrations in obstructive sleep apnea are related to insulin resistance.
    Liu A; Cardell J; Ariel D; Lamendola C; Abbasi F; Kim SH; Holmes TH; Tomasso V; Mojaddidi H; Grove K; Kushida CA; Reaven GM
    Sleep; 2015 May; 38(5):793-9. PubMed ID: 25348129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease.
    Zelber-Sagi S; Salomone F; Yeshua H; Lotan R; Webb M; Halpern Z; Santo E; Oren R; Shibolet O
    Liver Int; 2014 Jul; 34(6):e128-35. PubMed ID: 24118857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats.
    Qin B; Anderson RA; Kuzuya T; Kitaura Y; Shimomura Y
    Atherosclerosis; 2012 Jun; 222(2):409-16. PubMed ID: 22546076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
    Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
    Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.
    Martin A; Lang S; Goeser T; Demir M; Steffen HM; Kasper P
    Curr Atheroscler Rep; 2022 Jul; 24(7):533-546. PubMed ID: 35507279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease.
    Zhang L; Zhang Z; Li Y; Liao S; Wu X; Chang Q; Liang B
    Sci Rep; 2015 Nov; 5():15970. PubMed ID: 26522240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9.
    Quispe R; Al-Hijji M; Swiger KJ; Martin SS; Elshazly MB; Blaha MJ; Joshi PH; Blumenthal RS; Sniderman AD; Toth PP; Jones SR
    J Clin Lipidol; 2015; 9(4):511-8.e1-5. PubMed ID: 26228668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.